PH12015502000A1 - Processes and intermediates for preparing a medicament - Google Patents
Processes and intermediates for preparing a medicamentInfo
- Publication number
- PH12015502000A1 PH12015502000A1 PH12015502000A PH12015502000A PH12015502000A1 PH 12015502000 A1 PH12015502000 A1 PH 12015502000A1 PH 12015502000 A PH12015502000 A PH 12015502000A PH 12015502000 A PH12015502000 A PH 12015502000A PH 12015502000 A1 PH12015502000 A1 PH 12015502000A1
- Authority
- PH
- Philippines
- Prior art keywords
- intermediates
- processes
- medicament
- preparing
- useful
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 abstract 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 abstract 1
- 229960001507 ibrutinib Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Disclosed is a process for the preparation of the following compounds: (I), (II) where R1, R1a and R2a have the definitions in the description, as well as a process to prepare other intermediates that may be useful to synthesise downstream products, especially compounds that are useful as medicaments, for instance Bruton's tyrosine kinase (Btk) inhibitors such as ibrutinib. Also disclosed are other processes, other intermediates and compounds per se.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786842P | 2013-03-15 | 2013-03-15 | |
| EP13159470 | 2013-03-15 | ||
| EP13197813 | 2013-12-17 | ||
| PCT/EP2014/054621 WO2014139970A1 (en) | 2013-03-15 | 2014-03-11 | Processes and intermediates for preparing a medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12015502000A1 true PH12015502000A1 (en) | 2016-01-11 |
| PH12015502000B1 PH12015502000B1 (en) | 2023-01-11 |
Family
ID=50239639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2015/502000A PH12015502000B1 (en) | 2013-03-15 | 2014-03-11 | Processes and intermediates for preparing a medicament |
Country Status (5)
| Country | Link |
|---|---|
| CL (1) | CL2015002668A1 (en) |
| HK (1) | HK1216178A1 (en) |
| IL (1) | IL240533A0 (en) |
| PE (1) | PE20211448A1 (en) |
| PH (1) | PH12015502000B1 (en) |
-
2014
- 2014-03-11 PE PE2020001350A patent/PE20211448A1/en unknown
- 2014-03-11 HK HK16104203.7A patent/HK1216178A1/en unknown
- 2014-03-11 PH PH1/2015/502000A patent/PH12015502000B1/en unknown
-
2015
- 2015-08-12 IL IL240533A patent/IL240533A0/en active IP Right Review Request
- 2015-09-14 CL CL2015002668A patent/CL2015002668A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1216178A1 (en) | 2016-10-21 |
| PE20211448A1 (en) | 2021-08-05 |
| CL2015002668A1 (en) | 2016-03-04 |
| PH12015502000B1 (en) | 2023-01-11 |
| NZ711026A (en) | 2021-01-29 |
| IL240533A0 (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY194905A (en) | Processes and Intermediates for Preparing a Medicament | |
| JO3453B1 (en) | Benzamid derivatives to inhibit the activity of abl1, abl2 and bcr-abl1 | |
| MX2021007432A (en) | Compounds and compositions for inhibiting the activity of shp2. | |
| EA030383B9 (en) | Bicyclically substituted uracils, processes for preparation thereof, use thereof, medicament and method for treatment using same | |
| SA515360007B1 (en) | Heteroaromatic compounds as bruton's tyrosine kinase (BTK) inhibitors | |
| MX2016003582A (en) | Compound inhibiting kinase activities of btk and/or jak3. | |
| MY173877A (en) | Branched 3-phenylpropionic acid derivatives and the use thereof | |
| MX336214B (en) | Pyrrolotriazinone derivatives as pi3k inhibitors. | |
| MX357305B (en) | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1. | |
| PH12014500460A1 (en) | Substituted annellated pyrimidine and the use thereof | |
| EA201492005A1 (en) | BENZAMIDE DERIVATIVES TO INHIBIT ACTIVITY ABL1, ABL2 AND BCR-ABL1 | |
| MX2013011691A (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses. | |
| PH12016500003A1 (en) | Compounds and compositions as inhibitors of mek | |
| MY175804A (en) | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments | |
| UA113962C2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT | |
| MX2016000480A (en) | High potency pancreatin pharmaceutical compositions. | |
| TN2015000095A1 (en) | Macrolide derivatives, preparation thereof and therapeutic use thereof | |
| PH12015502000B1 (en) | Processes and intermediates for preparing a medicament | |
| TN2013000128A1 (en) | Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation | |
| TN2014000085A1 (en) | Substituted annellated pyrimidine and the use thereof |